In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed ...

At a median follow-up of 18 months, the OS rate was 95% and the DFS rate was 88%. 14 Long-term follow-up at a median of 53 ...

CS Genetics, an innovative genomics technology company, today announced a strategic partnership with ROSALIND®, the premier SaaS platform empowering life science research across diverse technologies.

Differential expression of other cell cycle-associated regulators during ... positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501–12 (1999).

Researchers used infrared light to capture clear images of biomolecules inside cells — something that was previously not ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.

Research explores the intricate relationship between health, beauty, and aging in women, emphasizing the critical roles of ...

Breast Cancer Growth Rate and Doubling TimeMedically reviewed by Doru Paul, MDMedically reviewed by Doru Paul, MDPeople with ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, mature data from its ...

In Type 1 diabetes (T1D), insulin-producing β-cells are killed by islet-infiltrating immune cells in a process called “insulitis”. T1D results in a critical requirement for exogenous insulin and ...